Biologic Excipients Market size is anticipated to grow at a commendable pace during the forecast timeline of 2023-2032. Excipients are being increasingly used by medical researchers as they offer many benefits, including assistance in the creation of novel therapies and improving the solubility of active pharmaceutical ingredients (APIs), among others.
Biologic medications are being formulated to target specific parts of the immune system and treat diseases, such as psoriatic arthritis, which affects an estimated 2.4 million people in the U.S., thereby promoting industry gains in the coming years.
Drug delivery technologies are also undergoing notable improvements to enhance patient outcomes. Moreover, the prevalence of autoimmune and inflammatory disorders is increasing across the globe.
Based on product, the biologic excipients market is segmented into organic, inorganic, and others. The market share from the inorganic product segment is predicted to register an appreciable CAGR through 2032. Some of the major factors escalating the product adoption include the high physical & chemical stability offered by calcium phosphate and its compatibility with several APIs.
The number of individuals suffering from bone-related conditions, such as osteoporosis is rising at a steady rate. Calcium phosphate can function as a hydrophilic porous carrier to boost the oral bioavailability of drugs that have low water solubility and can also be used in medicines that relieve the symptoms associated with these ailments, thereby fueling product consumption.
Based on formulation, global biologic excipients market is divided into oral, topical, parenteral, and other formulations. The industry revenue from the topical formulation segment will increase significantly during the forecast timeline. Topical drug therapy is one of the preferred methods of treating psoriasis as it directly targets the affected skin without causing any adverse reactions, further propelling the creation of topical formulations. Such factors will, in turn, foster industry growth over the forecast period.
On the regional front, Asia Pacific biologic excipients market outlook is set to register a considerable CAGR through 2032. Technologies such as artificial Intelligence are being used on a large scale across the region’s healthcare sector and have shown strong application potential in the drug discovery & development process in developing countries, including China. Cancer cases are also witnessing a prolific rise across Asian regions such as South Korea. In 2022, over 274,488 new cases of cancer and 81,277 deaths from the ailment were estimated to occur in Korea. Such scenarios will augment the need for biopharma excipients, given the burgeoning research efforts in the region to identify the benefits of using biologic excipients in the treatment of leukemia and other cancers.
Some of the major organizations involved in biologic excipients market include Kerry Group PLC, Croda International, Colorcon Inc. (BPSI Holdings), Dupont De Nemours, Inc., Evonik Industries AG (Rag-Stiftung), BASF SE, Roquette Frères, Meggle USA, and Ashland, among others.